1. Home
  2. CVM
  3. CVM News

Latest Cel-Sci Corporation (CVM) News on December 18, 2024

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
CVM

Business Wire

6 days ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

CVM

Zacks Small Cap Research

10 days ago

CVM: CRO Selected for Registrational Trial

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
CVM

Business Wire

a month ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
CVM

Business Wire

2 months ago

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
CVM

Business Wire

3 months ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation
CVM

Business Wire

3 months ago

CEL-SCI’s Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress
CVM

Business Wire

3 months ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
CVM

Business Wire

3 months ago

The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study
CVM

Zacks Small Cap Research

4 months ago

CVM: Start Your Engines – FDA Green Lights Confirmatory Registration Study

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
CVM

Business Wire

4 months ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

CVM

Associated Press Finance

4 months ago

Cel-Sci: Fiscal Q3 Earnings Snapshot

CEL-SCI Announces Closing of $10.8 Million Offering
CVM

Business Wire

5 months ago

CEL-SCI Announces Closing of $10.8 Million Offering

CVM

MT Newswires

5 months ago

Cel-Sci Prices $10.8 Million Offering

CEL-SCI Announces Pricing of $10.8 Million Offering
CVM

Business Wire

5 months ago

CEL-SCI Announces Pricing of $10.8 Million Offering

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
CVM

Business Wire

5 months ago

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

CVM

MT Newswires

5 months ago

Cel-Sci Appoints Robert Watson Board's Chair

CEL-SCI Appoints Robert Watson as Chairperson of the Board
CVM

Business Wire

5 months ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CVM

Business Wire

6 months ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Italian energy company targets Britain for fleet of 20 mini-nukes
CVM

The Telegraph

6 months ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
CVM

Simply Wall St.

6 months ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
CVM

Simply Wall St.

6 months ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks
CVM

Simply Wall St.

6 months ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
CVM

Motley Fool

6 months ago

4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?
CVM

Simply Wall St.

6 months ago

Should You Be Adding Mueller Water Products (NYSE:MWA) To Your Watchlist Today?

Seoul resumes loudspeaker propaganda against North
CVM

AFP

6 months ago

Seoul resumes loudspeaker propaganda against North

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)
CVM

Simply Wall St.

6 months ago

Graham Full Year 2024 Earnings: EPS: US$0.42 (vs US$0.035 in FY 2023)

Spirit Airlines not considering Chapter 11 bankruptcy, CNBC reports
CVM

Reuters

6 months ago

Spirit Airlines not considering Chapter 11 bankruptcy, CNBC reports

Decisions of the Ordinary General Shareholders' Meeting of Novaturas AB
CVM

GlobeNewswire

6 months ago

Decisions of the Ordinary General Shareholders' Meeting of Novaturas AB

AllianceBernstein: Office Space: Looking Past the Doom and Gloom
CVM

ACCESSWIRE

6 months ago

AllianceBernstein: Office Space: Looking Past the Doom and Gloom

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
CVM

ACCESSWIRE

6 months ago

Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine

Sage Potash Grants Stock Options
CVM

CNW Group

6 months ago

Sage Potash Grants Stock Options

Aqua-Tots Swim School Splashes Into Summer With Highly-Anticipated Grand Opening in Henderson, Nevada
CVM

GlobeNewswire

6 months ago

Aqua-Tots Swim School Splashes Into Summer With Highly-Anticipated Grand Opening in Henderson, Nevada

BW Energy: Mandatory notifications of trade by primary insiders and close associates
CVM

GlobeNewswire

6 months ago

BW Energy: Mandatory notifications of trade by primary insiders and close associates

DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio
CVM

Newsfile

6 months ago

DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
CVM

Business Wire

6 months ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

CVM: Confirmatory Study Clarity
CVM

Zacks Small Cap Research

7 months ago

CVM: Confirmatory Study Clarity

CVM

Associated Press Finance

7 months ago

Cel-Sci: Fiscal Q2 Earnings Snapshot

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CVM

Business Wire

7 months ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

CVM

MT Newswires

7 months ago

Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CVM

Business Wire

7 months ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CVM

Business Wire

8 months ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

CVM

Zacks Small Cap Research

8 months ago

CVM: Parallel Engagement on Four Fronts

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
CVM

Business Wire

9 months ago

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

CEL-SCI Corporation Issues Letter to Shareholders
CVM

Business Wire

9 months ago

CEL-SCI Corporation Issues Letter to Shareholders

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
CVM

Business Wire

10 months ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

CVM

Associated Press Finance

10 months ago

Cel-Sci: Fiscal Q1 Earnings Snapshot

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
CVM

Business Wire

10 months ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
CVM

Business Wire

10 months ago

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
CVM

Business Wire

10 months ago

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
CVM

Business Wire

a year ago

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

USCB Financial Holdings, Inc. Initiates Quarterly Cash Dividend Program and Announces Declaration of First Cash Dividend
CVM

GlobeNewswire

a year ago

USCB Financial Holdings, Inc. Initiates Quarterly Cash Dividend Program and Announces Declaration of First Cash Dividend

Franklin Financial Services (NASDAQ:FRAF) Will Pay A Dividend Of $0.32
CVM

Simply Wall St.

a year ago

Franklin Financial Services (NASDAQ:FRAF) Will Pay A Dividend Of $0.32

Bassett Furniture Industries Inc (BSET) Reports Fiscal Q4 Earnings Amidst Market Challenges
CVM

GuruFocus.com

a year ago

Bassett Furniture Industries Inc (BSET) Reports Fiscal Q4 Earnings Amidst Market Challenges

CVM

Business Wire

a year ago

Mytheresa Announces Second Quarter of Fiscal Year 2024 Earnings Release and Conference Call; Participating in Upcoming Investor Conferences

eGain to Announce Fiscal 2024 Second Quarter Financial Results on February 8, 2024
CVM

GlobeNewswire

a year ago

eGain to Announce Fiscal 2024 Second Quarter Financial Results on February 8, 2024

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?
CVM

Zacks

a year ago

Wayfair (W) Soars 10.3%: Is Further Upside Left in the Stock?

Shareholders in Lifetime Brands (NASDAQ:LCUT) are in the red if they invested three years ago
CVM

Simply Wall St.

a year ago

Shareholders in Lifetime Brands (NASDAQ:LCUT) are in the red if they invested three years ago

Profound Medical Announces Non-Brokered Private Placement
CVM

GlobeNewswire

a year ago

Profound Medical Announces Non-Brokered Private Placement

FARO Technologies Announces CFO Transition
CVM

PR Newswire

a year ago

FARO Technologies Announces CFO Transition

Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?
CVM

Simply Wall St.

a year ago

Is Erasca (NASDAQ:ERAS) In A Good Position To Invest In Growth?

Oatly Launches Two New Oatmilk Varieties, Marking the Company’s First Major Innovations to its Core North American Beverage Portfolio in Five Years
CVM

GlobeNewswire

a year ago

Oatly Launches Two New Oatmilk Varieties, Marking the Company’s First Major Innovations to its Core North American Beverage Portfolio in Five Years

CVM

Zacks Small Cap Research

a year ago

CVM: Fiscal Year 2023 in Review

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
CVM

GlobeNewswire

a year ago

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
CVM

GlobeNewswire

a year ago

Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside
CVM

InvestorPlace

a year ago

Low-Cost, High-Potential: 3 Stocks Under $5 with Surprising Upside

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
CVM

Business Wire

a year ago

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

CVM

Zacks Small Cap Research

a year ago

CVM: NICE To Have Your Support

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
CVM

Business Wire

a year ago

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully
CVM

Simply Wall St.

a year ago

We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully

VIZSLA SILVER REPORTS ADDITIONAL HIGH-GRADE INTERCEPTS ON THE COPALA AND COPALA 2 STRUCTURES
CVM

CNW Group

a year ago

VIZSLA SILVER REPORTS ADDITIONAL HIGH-GRADE INTERCEPTS ON THE COPALA AND COPALA 2 STRUCTURES

Dakota Gold Corp. Issues Correction to November 21, 2023 News Release Announced Earlier Today
CVM

Newsfile

a year ago

Dakota Gold Corp. Issues Correction to November 21, 2023 News Release Announced Earlier Today

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
CVM

Business Wire

a year ago

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
CVM

Business Wire

a year ago

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

CVM

Business Wire

a year ago

Legg Mason Partners Fund Advisor, LLC Announces Distributions for the Months of December 2023, January and February 2024

CVM

GlobeNewswire

a year ago

Kandi America Partners with Peavey Mart to Expand Kandi Products into Canada

Kandi Technologies Group, Inc. (NASDAQ:KNDI) Q3 2023 Earnings Call Transcript
CVM

Insider Monkey

a year ago

Kandi Technologies Group, Inc. (NASDAQ:KNDI) Q3 2023 Earnings Call Transcript

12 Best Day Trading Stocks To Buy
CVM

Insider Monkey

a year ago

12 Best Day Trading Stocks To Buy

CVM

Associated Press Finance

a year ago

Alta Equipment: Q3 Earnings Snapshot

MidCap Financial Investment Corporation Announces Merger Agreements with Apollo Senior Floating Rate Fund Inc. and Apollo Tactical Income Fund Inc.
CVM

GlobeNewswire

a year ago

MidCap Financial Investment Corporation Announces Merger Agreements with Apollo Senior Floating Rate Fund Inc. and Apollo Tactical Income Fund Inc.

Sprott (TSE:SII) Could Be A Buy For Its Upcoming Dividend
CVM

Simply Wall St.

a year ago

Sprott (TSE:SII) Could Be A Buy For Its Upcoming Dividend

Ranger Energy Services, Inc. (NYSE:RNGR) Q3 2023 Earnings Call Transcript
CVM

Insider Monkey

a year ago

Ranger Energy Services, Inc. (NYSE:RNGR) Q3 2023 Earnings Call Transcript

Share on Social Networks: